OPKO Health, Inc. (LON:0KCS)

Market Cap	682.38M -21.5%
Revenue (ttm)	450.91M -14.9%
Net Income	-167.68M
EPS	-0.22
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,736
Average Volume	10,733
Open	1.200
Previous Close	1.171
Day's Range	1.180 - 1.200
52-Week Range	1.130 - 1.870
Beta	1.52
RSI	48.84
Earnings Date	Feb 26, 2026

About OPKO Health

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune syst...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2006
• Employees: 2,275
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0KCS

Financial Performance

In 2025, OPKO Health's revenue was $606.88 million, a decrease of -14.90% compared to the previous year's $713.14 million. Losses were -$225.68 million, 324.0% more than in 2024.

Financial numbers in USD